Unique ID issued by UMIN | UMIN000034312 |
---|---|
Receipt number | R000039118 |
Scientific Title | Observation of changes in comprehensive immune pathology in chemotherapy including Nivolumab for patients with refractory malignant pleural mesothelioma |
Date of disclosure of the study information | 2018/12/01 |
Last modified on | 2020/12/26 12:06:03 |
Observation of changes in comprehensive immune pathology in chemotherapy including Nivolumab for patients with refractory malignant pleural mesothelioma
Observation of changes in comprehensive immune pathology in chemotherapy including Nivolumab for patients with refractory malignant pleural mesothelioma
Observation of changes in comprehensive immune pathology in chemotherapy including Nivolumab for patients with refractory malignant pleural mesothelioma
Observation of changes in comprehensive immune pathology in chemotherapy including Nivolumab for patients with refractory malignant pleural mesothelioma
Japan | Asia(except Japan) |
Malignant pleural mesothelioma
Pneumology |
Malignancy
NO
Prediction of the effect of Nivolumab on malignant pleural mesothelioma Search for biomarkers
Others
Observation of comprehensive immune pathology before and after chemotherapy including Nivolbam is performed on exacerbating malignant pleural mesothelioma with progression and recurrence with exacerbation and at the time of judgment of efficacy in continuous treatment (or when a disease state changes) By doing so, we aim to search for biomarkers for predicting the effects of opigo in malignant pleural mesothelioma.
Exploratory
Pragmatic
Not applicable
Comprehensive station immune dynamics using peripheral blood before Bivolbam administration, 5 to 7 days after administration and after about 3 months
Search biomarkers after analysis
Interventional
Parallel
Non-randomized
Single blind -participants are blinded
No treatment
NO
NO
NO
Numbered container method
2
Diagnosis
Other |
Malignant pleural mesothelioma of unresectable progression and recurrence exacerbated after cancer chemotherapy
Elderly subjects with non-tumor types (including mesothelioma), non-asbestos exposure and nonimmune diseases almost agreeing with age
20 | years-old | <= |
85 | years-old | >= |
Male and Female
Malignant pleural mesothelioma of unresectable progression and recurrence exacerbated after cancer chemotherapy
Initial and resectable malignant pleural mesothelioma
30
1st name | Yasumitsu |
Middle name | |
Last name | Nishimura |
Kawasaki Medical School
Department of Hygiene
701-0192
577 Mastushima, Kurashiki, Okayama, Japan
08063084002
yas@med.kawasaki-m.ac.jp
1st name | Yasumitsu |
Middle name | |
Last name | Nishimura |
Kawasaki Medical School
Department of Hygiene
7010192
577 Mastushima, Kurashiki, Okayama, Japan
086-462-1111
yas@med.kawasaki-m.ac.jp
Kawasaki Medical School
Health labor occupational injury disease clinical research project subsidy
Japanese Governmental office
Kawasaki Medical School
Faculty research expenses, project research expenses
Kawasaki Medical School Ethics Committee
577 Matsushima
08063084002
kmsrec@med.kawasaki-m.ac.jp
NO
2018 | Year | 12 | Month | 01 | Day |
Unpublished
Enrolling by invitation
2018 | Year | 09 | Month | 26 | Day |
2018 | Year | 10 | Month | 30 | Day |
2018 | Year | 12 | Month | 01 | Day |
2022 | Year | 03 | Month | 31 | Day |
2018 | Year | 09 | Month | 28 | Day |
2020 | Year | 12 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039118
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |